TriSalus Life Sciences, Inc./$TLSI
1D1W1MYTD1Y5YMAX
Capital at risk
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
- Ticker
- $TLSI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 102
- Headquarters
- Westminster, United States
- Website
- trisaluslifesci.com
TLSI Metrics
BasicAdvanced
$302M
-
-$1.15
0.43
-
Price and volume
Market cap
$302M
Beta
0.43
52-week high
$7.95
52-week low
$2.20
Average daily volume
152K
Financial strength
Current ratio
5.348
Quick ratio
4.721
Long term debt to equity
5.219
Total debt to equity
5.256
Interest coverage (TTM)
-5.23%
Profitability
EBITDA (TTM)
-29.949
Gross margin (TTM)
85.79%
Net profit margin (TTM)
-62.59%
Operating margin (TTM)
-67.68%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-36.75%
Return on equity (TTM)
438.31%
Valuation
Price to revenue (TTM)
5.436
Price to book
45.99
Price to tangible book (TTM)
45.99
Price to free cash flow (TTM)
-10.525
Free cash flow yield (TTM)
-9.50%
Free cash flow per share (TTM)
-0.466
Growth
Revenue change (TTM)
25.25%
Earnings per share change (TTM)
-2.99%
3-year revenue growth (CAGR)
45.13%
3-year earnings per share growth (CAGR)
-29.20%
Bulls say / Bears say
Generated second quarter revenue of $11.4 million, representing a 1.7% year-over-year increase and solid sequential growth, indicative of expanding TriNav adoption (Business Wire).
On June 17, 2026, CMS established a permanent HCPCS G-code for vascular embolization procedures with a pressure-generating catheter, enabling reimbursement in office-based labs and significantly enlarging the addressable market (SEC filed Form 10-Q).
Closed the quarter with $46.3 million in cash and cash equivalents—bolstered by a $46 million equity raise—providing sufficient runway for commercial expansion and pipeline development (Business Wire).
Operating loss widened to $9.8 million from $7.3 million year-over-year and adjusted EBITDA loss grew to $7.1 million from $5.3 million, reflecting escalating cash burn amid commercial build-out (Business Wire).
Sales and marketing expenses surged to $11.4 million—up nearly 60% year-over-year—potentially straining margins if revenue growth does not continue apace (Business Wire).
Pomerantz LLP has launched an investor investigation into potential securities fraud by TriSalus and its officers, introducing legal and reputational risks that could divert management focus and incur costs (PR Newswire).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Upcoming events
No upcoming events
TLSI News
AllArticlesVideos
Funds containing TLSI
Fund name | Fund size | $TLSI weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.